Skip to content
value.today

Cytocentrics, Inc.

🇺🇸 San Antonio, Texas, USABiotechnologyFounded 2014
Total raised
$16 M
1 round on record
Latest round
$16 M
Mar 2015
First round on record
Mar 2015
Today
Private
No later event on record

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cytocentrics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2018$2 MIssued in a merger or acquisitionUnder $2 million

Cytocentrics, Inc.: Private sale, Mar 2018

Investors in this round

3 investors had bought by the notice of Mar 15, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$90,000
Finders' fees
none
Paid to its own people
$250,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • James R. Garvin · Executive Officer, Director
  • Alan R. Dean · Director
  • Ian R. Clements · Director
  • Paul R. Castella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Danielle Hughes (CRD 2189447) · broker-dealer Divine Capital Markets (CRD 118212) · New York, New YorkSold in CA, FL, IL, MD, MI, MN, NY, WA

Remarks in the notice

  • On a merger: “Intended merger”

Signed by James R. Garvin, Ceo. Source: SEC Form D, newest notice filed Mar 15, 2018. Read the notice at the SEC.

equitySEC
Mar 2018$2 MIssued in a merger or acquisitionUnder $2 million

Cytocentrics, Inc.: Private sale, Mar 2018

Investors in this round

3 investors had bought by the notice of Mar 16, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$90,000
Finders' fees
none
Paid to its own people
$250,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • James R. Garvin · Executive Officer, Director
  • Alan R. Dean · Director
  • Ian R. Clements · Director
  • Paul R. Castella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Danielle Hughes (CRD 2189447) · broker-dealer Divine Capital Markets (CRD 118212) · New York, New YorkSold in CO, NY

Remarks in the notice

  • On a merger: “Intended merger”

Signed by James R. Garvin, Ceo. Source: SEC Form D, newest notice filed Mar 16, 2018. Read the notice at the SEC.

equitySEC
Mar 2015$16 MNo. 1$10 to $50 million

Cytocentrics, Inc.: Raise no. 1, Mar 2015

Investors in this round

11 investors had bought by the notice of Jan 23, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $22 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$137,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James R. Garvin · Executive Officer, Director · Chief Executive Officer, President, Secretary and Treasurer
  • Alan R. Dean · Director
  • Ian R. Clements · Director
  • Paul R. Castella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jim Garvin (CRD 6219942) · broker-dealer Divine Capital Markets LLC (CRD 118212) · New York, New YorkSold in TX

Signed by James R. Garvin, Ceo. Source: SEC Form D and 3 amendments, newest notice filed Jan 23, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cytocentrics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2018).

    SEC Form D · Mar 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2018

That is all the official record says: Cytocentrics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cytocentrics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cytocentrics, Inc.
NameRoleNamed in
James R. GarvinExecutive officerMar 2018
Alan R. DeanDirectorMar 2018
Ian R. ClementsDirectorMar 2018
James R. GarvinDirectorMar 2018
Paul R. CastellaDirectorMar 2018